Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H41N3O5 |
| Molecular Weight | 523.6636 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC3=C(N(CCCOC(=O)C(C)(C)C)C=C3)C(=C2)C(N)=O
InChI
InChIKey=CTMYLDUPTAZFCT-OAQYLSRUSA-N
InChI=1S/C30H41N3O5/c1-6-36-25-10-7-8-11-26(25)37-17-13-32-21(2)18-22-19-23-12-15-33(27(23)24(20-22)28(31)34)14-9-16-38-29(35)30(3,4)5/h7-8,10-12,15,19-21,32H,6,9,13-14,16-18H2,1-5H3,(H2,31,34)/t21-/m1/s1
| Molecular Formula | C30H41N3O5 |
| Molecular Weight | 523.6636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:08:55 GMT 2025
by
admin
on
Mon Mar 31 23:08:55 GMT 2025
|
| Record UNII |
9529MK8HWG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9529MK8HWG
Created by
admin on Mon Mar 31 23:08:55 GMT 2025 , Edited by admin on Mon Mar 31 23:08:55 GMT 2025
|
PRIMARY | |||
|
9872508
Created by
admin on Mon Mar 31 23:08:55 GMT 2025 , Edited by admin on Mon Mar 31 23:08:55 GMT 2025
|
PRIMARY | |||
|
KRG-3332(FREE BASE)
Created by
admin on Mon Mar 31 23:08:55 GMT 2025 , Edited by admin on Mon Mar 31 23:08:55 GMT 2025
|
PRIMARY | Originator: Kissei Pharmaceutical; Class: Antiglaucomas; Mechanism of Action: Alpha 1a adrenergic-receptor antagonists; Highest Development Phase: Discontinued for Glaucoma use | ||
|
239463-68-4
Created by
admin on Mon Mar 31 23:08:55 GMT 2025 , Edited by admin on Mon Mar 31 23:08:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The companies say that the new compound is a highly-selective alpha-1A receptor antagonist, administered as an eye-drop which is expected to lower intraocular pressure in glaucoma patients by facilitating the outflow of fluid from the eye. Pharmacological studies in animals have shown that this efficacy is well-maintained over time.
|
||
|
ACTIVE MOIETY |
Novartis Ophthalmics last week announced that it had entered a license option agreement with Kissei Pharmaceutical Co. Ltd. for new glaucoma agent KRG-3332, a highly selective alpha 1A receptor. Studies in animals show the agent successfully reduces intraocular pressure and that efficacy is well-maintained over time.
|
